title: Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
abstract: BACKGROUND
  Procedural and clinical outcomes in patients with very long (>30mm) coronary lesions who underwent stent-based percutaneous coronary interventions are still unfavorable. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and Xpedition everolimus-eluting stents (X-EES) for patients with de novo very long coronary lesions.
  
  
  METHODS
  This comparative single-centre, retrospective study compared long R-ZES and X-EES in consecutive patients admitted with very long (≥30mm) native ACC/AHA type C coronary lesions in 2014. All patients were followed up clinically at 1, 3, 6 and 12months. In this study, only symptom-driven angiogram was advised. The study end point was to evaluate immediate procedural success and one-year rate of target lesion failure (TLF), which is a composite of cardiac death, target lesion myocardial infarction, or target lesion revascularization (TLR).
  
  
  RESULTS
  Total number of patients enrolled in this study was 185 (R-ZES=107; X-EES=78). The baseline characteristics and post procedural success rate were similar between R-ZES and X-EES groups, including the post stenting lesion lengths (36.6±1.92mm vs 40.71±6.175mm, P=0.09). At 12-month follow-up, there were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes). Procedural success was achieved in 94% in R-ZES group and 93% in X-EES group (P=0.24). The incidence of TLF was 5% in R-ZES and 4% in X-EES groups (HR-1.25; 95% CI-0.86-5.6; P=0.19).
  
  
  CONCLUSIONS
  Patients with de novo long coronary artery disease, R-ZES implantation showed similar clinical outcome as compared with X-EES implantation.
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India. Electronic address: dr_soumyapatra@rediffmail.com.
authors.forename: Soumya
authors.initials: S
authors.lastname: Patra
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Rabindra Nath
authors.initials: RN
authors.lastname: Chakraborty
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Arindam
authors.initials: A
authors.lastname: Pande
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Suvro
authors.initials: S
authors.lastname: Banerjee
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Manabhanjan
authors.initials: M
authors.lastname: Jena
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Prakash Chandra
authors.initials: PC
authors.lastname: Mandal
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Swapan Kumar
authors.initials: SK
authors.lastname: De
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Aftab
authors.initials: A
authors.lastname: Khan
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Sankha Suvro
authors.initials: SS
authors.lastname: Das
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Debashish
authors.initials: D
authors.lastname: Ghosh
authors.affiliation: Department of Cardiology, Apollo Gleneagles Hospitals & Apollo Heart Institute, Kolkata, India.
authors.forename: Raja
authors.initials: R
authors.lastname: Nag
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007194:India; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus
keywords: Coronary lesion; De novo; Drug-eluting stent; Long segment